Progress in research on end-stage non-small cell lung cancer treatment

Summary: Lung cancer is one of the most fatal malignant neoplasms, with late detection, rapid progress, poor prognosis and extremely low sensitivity to routine chemotherapy, with five years of survival hovering below 20 per cent for decades. The discovery of EGFR target-to-pharmaceuticals has created new hope for the treatment of the NSCI|C, and EGF gefiti “b” (Gibidini) and LOTINib (Elotini) represent the EGFR 哟sineTKI (EgFRt) that has a good effect on non-small cell lung cancer (NSCLc) with certain EGFR mutations. Although some results have been achieved in the EGFR target for the treatment of non-small cell lung cancer (NSCLC), there are still many problems to be addressed. The World Health Organization (WHO) statistics show that lung cancer is currently the number one cause of cancer in the world, accounting for about 19 per cent of all malignant tumours. At present, China has a mortality rate of 40.57 million for lung cancer, and the incidence of this disease continues to increase. Lung cancer has four basic treatments: surgery, treatment, chemotherapy and target treatment. The best treatment for lung cancer varies from stage to stage and from pathological to pathological type. Target-oriented treatment is the treatment of defective genes and proteins that promote the development of cancer. In some lung cancer cells, these abnormal proteins are usually present in large quantities. Numerous studies have shown that the targeting of non-small cell lung cancer patients in phase IV can lead to longer life periods [1-3]. 1 Target-oriented treatment, with the progressive development of modern science and technology, is gradually gaining ground towards cytology, molecular biology and even genomic taxonomic diagnostics and treatment. And many tumor target treatment techniques were born. Target therapy is designed at cytological molecular levels to respond to a specific carcinogenicity point, which, when introduced in the body, selects the carcinogenicity and has the effect of treating the tumour cell to death, with little damage to normal tissue cells. The high-selection and low-toxicity characteristics of the target drug, the application of which has effectively prolonged the survival rate of non-small cell lung cancer (NSCLC) patients [4]. 2 The drugs for target treatment are currently used in two main types of drug for clinical use, namely, Gifidini, Erotini for skin growth factor receptor (EGFR) and kratini for melanoma lymphoma (ALK). Gifidini and Errotini are selective chegsine stimulant inhibitors, which are used to treat local late or transmissible non-small cell lung cancers that were previously chemically treated or not suitable for chemotherapy. Quetzoni is used to treat LAK positive local late and transferred non-small cell lung cancer. Kay. The other category is single-cloned antibodies (single antigens), which include cylindrons, which inhibit tumour vascular growth, and drugs, such as EGFRs, which are monotony antigens. A clinical trial[5] for the treatment of advanced lung cancer (ECOG4599) published in the New England magazine in 2006 opened the era of targeting and treatment of NSCLC. 3 The clinical study of target treatment for non-small-cell lung cancers was largely at an advanced stage of diagnosis and lost surgery opportunities. chemotherapy is inefficient and has a high level of adverse effects. Domestic and international clinical studies have confirmed that end-of-life non-small cell lung cancer can be treated with efficiency of up to 15 to 20 per cent [6] and low adverse effects, showing good clinical results. Zheng Gangnam et al.[7] observed the efficacy of regular chemotherapy (NSCLC) for non-small cell lung cancer in late stages of the Gibertini and platinum-containing programmes. It was concluded that the application of Gifidini to the late NSCLC was good and safe. Chen Chuyun et al.[8] conducted research on the model of an effective combination of treatment of non-small cell lung cancer in the end-stage combination of tumour target treatment for therapeutic drugs to improve the survival and quality of late-stage lung cancer patients. It is believed that the combination of the treatment of non-small-cell lung cancer at the end of the first check-up can improve the efficacy and survival of treatment and improve the quality of life, but that, despite some negative reactions, the treatment and care can be mitigated. A study on clinical efficacy and safety in the treatment of non-small cell lung cancers at the end of their life cycle conducted by Xiaoqin and others[9] found that Gifidini is a good target drug for non-small cell lung cancer, that it is effective and that it can significantly improve the quality of life of patients and have good clinical application prospects. A study of the efficacy, influence factors and side effects of the treatment of non-small cell lung cancer in late-stage Elotini by Li Wen Seng et al.[10] found that the treatment of late-stage non-small cell lung cancer was clearly effective, less adverse and more resistant. Ryo Yongjun et al.[11] observed the efficacy and adverse effects of the treatment of non-small cell lung cancer at the end of Erotini, which was considered to have a significant anti-tumour effect on non-small cell lung cancer at the end of the period, as an effective and durable target-oriented treatment. Roe Shizuku et al. [11] observed the effects of CT-led CT-led pulmonary punctures on lung cancer through microwave digestion (PMCT) and target-oriented treatment. PMTCT for non-small-cell lung cancer is reliable for tumours of 3.5 cm in diameter, and >3.5 cm is still largely or entirely active in in situ. 4 The side effects of end-to-end cancer target reversals to the treatment of drugs are innovations in pre-existing tumour treatment concepts and models, the pre-eminent advantages of individualisation, high efficacy, user-friendliness and less adverse effects being widely recognized, but the toxic side effects of lung cancer target treatment are still more evident, with common rashes, digestive reactions, bone marrow inhibition, heart toxicity, etc. The rash usually occurs between 7 and 10 days after the start of treatment, is self-healing and recirculated, is reversible and disappears quickly after the general treatment has been discontinued. One of the most common good effects of EGFR inhibitors is rash, with a high incidence of 79 ~88% [13], most of which is scabies. With regard to Chinese medicine, Guo Peng [14] discussed the relevance of changes in the health characteristics of Chinese medicine for the prevention and treatment of drug-related rashes, with a specific description of the rash identification; and Zenggwang [15] discussed the application of KIfidini treatment to non-small-cell lung cancers in the later stages.